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OSTEOARTHRITIS (OA) is the most common joint 
disorder affecting the majority of persons aged 65 
years or more, many of them suffering from pain and 
functional disability. Since OA is a heterogeneous 
condition presenting in a variety of ways, it is 
considered as a syndrome. This notion is supported 
by the highly variable way of presentation and 
differing patterns of disease expression. Whatever 
the causes and underlying disease processes are, the 
patient is most concerned about pain and disease 
related to functional disability. The reasons for 
consulting the physician are therefore pain relief 
and/or functional improvement. 
For symptomatic pain relief, analgesics, NSAIDs 
and intra-articular agents are widely used. How- 
ever, they carry a high profile of risks, probably 
including local detrimental effects. A new class of 
drugs (so-called slow-acting symptomatic OA 
drugs) are thought o offer symptomatic efficacy at 
a low-risk profile. 
Functional disability resulting from destructive 
changes of the osteoarthritic joint may be avoided 
or retarded through so-called chondroprotection. 
Up until now no single agent has been found to 
offer proven reduction in the progression of 
cartilage damage. Such disease modifying proper- 
ties in OA have been found in animal models, but 
not in humans. 
The studies presented at this symposium have 
focussed on aspects of both symptom relieving 
efficacy and disease-modifying properties. What- 
ever the underlying mechanisms leading to 
improved outcome of the osteoarthritic process 
are, the decisive questions are whether the OA 
patient himself will experience significant im- 
provements in pain and dysfunction. With regard 
to symptom relief, all respective studies have found 
statistically significant differences with improved 
pain in the chondroitin sulfate groups compared to 
placebo. In OA of the knee, additional positive 
findings included improved Lequesne's index and 
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decreased intake of analgesics or NSAIDs as 
escape medication. Studies examining OA of the 
knee covered 3, 6 and 12 months. The studies, 
supporting earlier work by other authors, suggest 
a slow-acting antisymptomatic efficacy of chon- 
droitin sulfate. 
Two studies have examined the osteoarthritic 
process as assessed by imaging techniques: one 
l-year study on OA of the knee, using a 
quantitative digitalized automatic image analysis 
technique for X-rays, and one 3-year study on OA 
of the fingers, using standard antero-posterior 
roentgenograms. The most interesting finding of 
the finger study, looking at the development of OA 
in previously normal IP joints, was the signifi- 
cantly lower number of patients with new erosive 
OA in the treatment group, suggesting a protection 
against erosive evolution under chondroitin sul- 
fate. Similarly, in patients with OA of the knee, a 
decrease in disease progression was found on 
X-rays. This latter finding, however, has to be 
interpreted with caution since the number of 
patients included was low and selection bias 
might have been critical. Moreover, the digitalized 
automatic X-ray technique is not yet validated and 
does not represent accepted standards in the 
assessment of OA. 
Although the underlying mechanisms of the 
effects of chondroitin sulfate on processes involved 
in the OA syndrome are far from clear, the studies 
presented support a slow-acting anti-osteoarthritic 
efficacy. Although there are some suggestions for 
structural modifying properties with regard to the 
finger joints, further studies are necessary. Such 
investigations should include accepted standards 
with respect to the techniques used (roentgeno- 
grams) and outcome assessments (pain, physical 
function as assessed by WOMAC or Lequesne's 
score) and patients global assessment. Investi- 
gations on structural changes require a study over 
2 or more years. To allow for shorter study periods 
and a smaller number of patients, research in newer 
techniques uch as MRI or microfocal radiographs 
requiring validation is eagerly awaited. 
